Most importantly, the USP7 inhibitor sensitizes tumor cells to chemotherapy by decreasing SAMHD1, which implies the potential of targeting USP7-SAMHD1-CtIP axis to improve chemosensitivity. Here, USP7 is linked to neoplasm.